Supplementary Table S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Authors: Ben Tran, Mark Voskoboynik, Sang-We Kim et al.

Publication:

Published: Unknown date

Source: Crossref

Back to Search View Original Cite This Article

Abstract

<jats:p><p>Supplementary Table S4. Baseline patient demographics and disease characteristics of patients receiving single-agent volrustomig 750 mg in the parallel phase I study in Japanese patients.</p></jats:p>

Keywords

psupplementary table baseline patient demographics

Supplementary Table S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Abstract

Keywords

Related Articles

Rearrangement of 2-(γ-aminopropyl)benzoxazoles into 2-(α-pyrrolinylamino)phenols: from serendipitous reaction discovery to anti-mycobacterial opportunities

How Manchester created Manchesterism: from music and culture to political power

Supplementary Figure S1 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy

Supplementary Table S7 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy

Supplementary Figure S6 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy